The European Society for Medical Oncology has announced the recipients of the ESMO Breast Cancer 2026 Merit Awards, recognizing first authors whose submitted abstracts were considered especially deserving of distinction at this year’s congress.
Presented as part of ESMO’s ongoing commitment to supporting the next generation of oncology leaders, the Merit Awards highlight investigators contributing meaningful scientific work to the evolving landscape of breast cancer research. The awards are available upon application and are granted to selected presenters whose abstracts demonstrate notable scientific merit.
Recognizing Emerging Scientific Contributions
This year’s awardees represent institutions and oncology centers across Europe, North America, and Latin America, reflecting the international scope of breast cancer research presented at ESMO Breast Cancer 2026.
The selected recipients include:
- Milana Arantza Bergamino, Barcelona, Spain
- Emily Berry, London, United Kingdom
- Giacomo Biganzoli, Milan, Italy
- Agostino Bucalo, Rome, Italy
- Renata Colombo Bonadio, São Paulo, Brazil
- Niamh Cunningham, London, United Kingdom
- Frederick Matthew Howard, Chicago, United States
- Flavia Jacobs, Milan, Italy
- Soraia Lobo-Martins, Brussels, Belgium
- Olga Martinez Saez, Barcelona, Spain
- Guilherme Nader Marta, Boston, United States
- Alejandra Rezqallah Aron, Barcelona, Spain
- Tommaso Ruelle, Genoa, Italy
- Paolo Tarantino, Boston, United States
- Carmine Valenza, Milan, Italy
- Karen Van Baelen, Leuven, Belgium
- Neelima Vidula, Boston, United States
- Guillermo Villacampa, Barcelona, Spain
A Spotlight on the Future of Breast Oncology
The ESMO Merit Awards continue to serve as an important platform for highlighting promising investigators and impactful scientific work within the global oncology community. By recognizing early and mid-career researchers presenting at the congress, the initiative helps amplify innovative ideas and supports continued academic development in breast cancer research.
ESMO Breast Cancer 2026 brings together clinicians, researchers, and advocates from around the world to discuss emerging data, therapeutic advances, translational science, and multidisciplinary approaches shaping the future of breast oncology.
As new treatment strategies and biomarker-driven approaches continue to redefine care, recognition programs such as the Merit Awards underscore the importance of supporting scientific excellence across all stages of oncology research.
Find more exclusive oncology content on OncoDaily
Written by Nare Hovhannisyan,MD